Show simple item record

dc.contributor.authorKankanamalage, Anushka C. Galasiti
dc.contributor.authorWeerawarna, Pathum M.
dc.contributor.authorKim, Yunjeong
dc.contributor.authorChang, Kyeong-Ok
dc.contributor.authorGroutas, William C.
dc.date.accessioned2016-04-01T15:41:04Z
dc.date.available2016-04-01T15:41:04Z
dc.date.issued2016-03-03
dc.identifier.citationKankanamalage, Anushka C. Galasiti; Weerawarna, Pathum M.; Kim, Yunjeong; Chang, Kyeong-Ok; Groutas, William C. 2016. Anti-norovirus therapeutics: a patent review (2010-2015). Expert Opinion on Therapeutic Patents, vol. 26:no. 3:pp 297-308en_US
dc.identifier.issn1354-3776
dc.identifier.otherWOS:000371320700001
dc.identifier.urihttp://dx.doi.org/10.1517/13543776.2016.1153065
dc.identifier.urihttp://hdl.handle.net/10057/11991
dc.descriptionClick on the DOI link to access the article (may not be free).en_US
dc.description.abstractIntroduction: Human noroviruses are the primary causative agents of acute gastroenteritis and are a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. An improved understanding of norovirus biology, as well as the pathogenic mechanisms underlying the disease, has provided the impetus for a range of intense exploratory drug discovery efforts targeting viral and host factors. Areas covered: An overview of norovirus inhibitors disclosed in the patent literature (2010-present) and Clinicaltrials.gov is presented. The review is further enriched and supplemented by recent literature reports. Expert opinion: Seminal discoveries made in recent years, including a better understanding of the pathobiology and life cycle of norovirus, the identification and targeting of multiple viral and host factors, the advent of a replicon system and a small animal model for the preclinical evaluation of lead compounds, and the availability of high resolution X-ray crystal structures that can be utilized in structure-based drug design and lead optimization campaigns, collectively suggest that a small molecule therapeutic and prophylactic for norovirus infection is likely to emerge in the not too distant future.en_US
dc.description.sponsorshipNational Institutes of Health under grant number R01AI109039.en_US
dc.language.isoen_USen_US
dc.publisherTaylor & Francis Groupen_US
dc.relation.ispartofseriesExpert Opinion on Therapeutic Patents;v.26:no.3
dc.subject3CL protease inhibitorsen_US
dc.subjectRdRp inhibitorsen_US
dc.subjectAttachment and entry inhibitorsen_US
dc.subjectNorovirus infectionen_US
dc.subjectHost factorsen_US
dc.titleAnti-norovirus therapeutics: a patent review (2010-2015)en_US
dc.typeArticleen_US
dc.rights.holder© 2016 Informa UK Limited, an Informa Group company.en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record